Fresenius in Risky Deal-making
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 98 (Table of Contents)
Published: 7 Jul-2008
DOI: 10.3833/pdr.v2008.i98.157 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Fresenius has recently become involved in a number of areas which may concern investors – namely the heparin controversy and the ‘non-approvable’ product Injectafer®...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS